Crinetics Pharmaceuticals, Inc.

As of June 30, 2026, Crinetics Pharmaceuticals Inc carries a market capitalization of 3.46B, placing it among publicly traded companies globally. Its enterprise value stands at 2.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Crinetics Pharmaceuticals Inc's next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Crinetics Pharmaceuticals Inc has 105.77M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 88.36, and the price-to-book ratio stands at 3.31.

These figures are as of June 30, 2026. The EV/Sales ratio of 66.22 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.44B versus a market cap of 3.46B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Crinetics Pharmaceuticals Inc maintains a current ratio of 15.57, meaning it holds 15.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Crinetics Pharmaceuticals Inc posted a negative return on equity (ROE) of -42.45, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.42, reflecting losses generated across the asset base. The company generates approximately 66,514.91 in revenue per employee across its workforce of 554.75, a quick read on workforce productivity versus industry peers.

As of the close on August 31, 2026, Crinetics Pharmaceuticals Inc's stock has gained approximately 178.11% over the past 52 weeks. The 50-day moving average sits at 65.97, while the 200-day moving average is 43.62.

Over the twelve months ended June 30, 2026, Crinetics Pharmaceuticals Inc generated 36.90M in revenue and converted that into -439.06M in net income, yielding earnings per share of -4.40. EBITDA reached -476.91M, while operating income came in at -480.62M.

As of June 30, 2026, Crinetics Pharmaceuticals Inc holds 1.06B in cash and equivalents against 41.31M in total debt, resulting in a net debt position of -48.58M. Total book value stands at 1.04B, with working capital of 1.02B providing operational flexibility.

Crinetics Pharmaceuticals Inc produced -369.83M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.33M in capital expenditures, free cash flow totaled -372.16M - equivalent to -3.73 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,302.52 and net profit margin of -1,189.88 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -11.41: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.83, meaning Crinetics Pharmaceuticals Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Crinetics Pharmaceuticals Inc has an Altman Z-Score of 16.20, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.